Biological membrane-carrying aneurysm clip

Information

  • Patent Grant
  • 8197500
  • Patent Number
    8,197,500
  • Date Filed
    Tuesday, August 1, 2006
    18 years ago
  • Date Issued
    Tuesday, June 12, 2012
    12 years ago
Abstract
An aneurysm clip has a biological membrane and a metal clip. The membrane is harvested from an animal, crosslinked, and then has its antigens minimized. The membrane also has an active layer coupled thereto. The metal clip has a first clip bar and a second clip bar that are attached to each in a biased manner, a first clip arm that extends perpendicularly from the second clip bar, and a second clip arm that extends perpendicularly from the first clip bar. A first end of the biological membrane is coupled to the first clip arm, and a second end of the biological membrane is coupled to the second clip arm in a manner that defines a receiving portion.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to a medical prosthesis for human implantation, and in particular, to an aneurysm clip for treating aneurysms.


2. Description of the Prior Art


Aneurysms are one of the most common vascular disorders. There are many treatment methods for aneurysm, but for an aneurysm of a certain morphology, using an aneurysm clip to clip the aneurysm cyst at the root (i.e., at the location parallel to the vascular wall) and to close the cyst is a simple treatment method which is particularly suitable for locations that are difficult to access. This method has been applied in clinical treatment for some time and the short term efficacy is very good. However, because the other side of the vascular wall perpendicular to the axis also becomes thinner due to elongation when the aneurysm is formed, closing one side of the aneurysm can make the other side even thinner and result in the risk that a new aneurysm might develop, thereby resulting in a less-than ideal treatment result. In addition, a conventional aneurysm clip is not effective for fusiform aneurysms.


In light of the above reasons, there still remains a need for an aneurysm clip which overcomes the drawbacks mentioned above.


SUMMARY OF THE DISCLOSURE

It is an object of the present invention to provide a biological membrane-carrying aneurysm clip that has a durable biological membrane which can wrap the outer circumference of the clipped blood vessel.


It is an object of the present invention to provide a biological membrane-carrying aneurysm clip that prevents further formation of aneurysms at the treatment location, and that prevents breakage of the thinner vessel wall.


It is another objective of the present invention to provide a method of preparing the biological membrane-carrying aneurysm clip.


In order to accomplish the objects of the present invention, the present invention provides an aneurysm clip having a biological membrane and a metal clip. The membrane is harvested from an animal, crosslinked, and then has its antigens minimized. The membrane also has an active layer coupled thereto. The metal clip has a first clip bar and a second clip bar that are attached to each in a biased manner, a first clip arm that extends perpendicularly from the second clip bar, and a second clip arm that extends perpendicularly from the first clip bar. A first end of the biological membrane is coupled to the first clip arm, and a second end of the biological membrane is coupled to the second clip arm in a manner that defines a receiving portion.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an aneurysm clip according to one embodiment of the present invention.



FIG. 2 is a cross-sectional view of the region labeled “A” of the aneurysm clip of FIG. 1.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention. The scope of the invention is best defined by the appended claims.


The present invention provides a biological membrane-carrying aneurysm clip that has a metal clip and a biological membrane. The metal clip is made of medical stainless steel or titanium alloys, and has a cross-lapping first clip bar and second clip bar, with the ends of the clip bars connected through a spring device. A first clip arm and a second clip arm are provided at the end of the half slip ring on the first clip bar and the end of the half slip ring on the second clip bar, respectively. The two ends of the biological membrane are connected to the first clip arm and the second clip arm, respectively, to form a membrane sheath. The biological membrane can be selected from porcine, bovine or ovine pleura, peritoneum, pericardium or small intestine submucosa, then prepared by crosslinking and fixation with a fixative, treated to minimize antigens, and then coated with a surface layer containing an active layer.


Animal tissues are easily degraded or decomposed by microorganisms, so that crosslinking and fixation with a fixative is required. Conventionally, glutaraldehyde is utilized as a fixative, but glutaraldehyde produces toxic radicals. However, aldehydes undergo crosslinking with proteins through the acetal reaction and toxic aldehydes are released when the crosslinked products are degraded, so that products fixed with an aldehyde have long-term residual toxicity. When epoxides, diamides, diisocyanates or carbodiimides are utilized as fixatives in place of aldehydes, this toxicity problem can be eliminated. When an epoxide is utilized, for example, proteins are crosslinked through a ring opening reaction of the epoxide, and reverse ring closure to form the epoxide back does not readily occur, and the degradation products are diols and polyols which can be metabolized by the body so that there is no risk of toxic aldehyde radicals. The stability of the animal tissues after treatment is also higher than those fixed with aldehydes. According to modern immunological theory, the antigenicity of animal tissues stems mainly from active groups located at specific sites and in specific conformations, and these active groups include —OH, —NH2, —SH, etc. The specific conformations result mainly from some specific hydrogen bonding formed by spiral protein chains. The specific sites and conformations are called antigen determinants. When treating the animal ligaments, one or several small, active reagents (e.g., acid anhydrides, acid chlorides, acylamides, epoxides, etc.) which can readily react with these groups are used to bind and block these groups, which in turn effectively minimizes the antigenicity, and in the meantime strong hydrogen bonding reagents (e.g., guanidine compounds) are utilized to form new hydrogen bonds and replace the inherent hydrogen bonding of the specific conformations, which changes the specific conformations and further effectively minimizes the antigenicity. The structure of the animal membranes cannot be easily altered after they have been crosslinked and fixed by non-aldehyde fixatives such as epoxides, and the tissues are not easily degraded or decomposed, and collagenase only begins to phagocytize and degrade them due to the synergistic effect of fibrinolysin and kallikrein released by nascent tissues, which means that the new ligament tissues have sufficient time to grow and take hold, while no toxic radicals remain. The immunogenicity is effectively minimized by blocking the active groups in the proteins and changing the conformation, and the resulting membrane has no chronic immune rejection while having excellent biocompatibility. When applying the biological membrane-carrying aneurysm clip, the circumference of the blood vessel at the clipped site is wrapped by the membrane, and the biological membrane and the outer membrane of the blood vessel can grow together, resulting in biological strengthening of the blood vessel and excellent treatment efficacy.


Furthermore, the tissue compatibility is improved by modifying the surface by incorporating an active component (as described below), including a specific polypeptide and glucosaminoglycan. One example of the polypeptide is the polypeptide consisting of 16 lysines (K16), glycine (G), arginine (R), asparatic acid (D), serine (S), proline (P) and cysteine (C), and the glucosaminoglycans are hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylated heparin sulfate and keratan sulfate. These active components are beneficial in facilitating growth of the cells on the wall of the wrapped blood vessel and fusing with the wall of the blood vessel, enhancing the bio-strength.


Method


A method of preparing the biological membrane-carrying aneurysm clip according to the present invention comprises the following steps, wherein the biological membrane utilizes natural durable tissues from animals:


1. Pretreatment: Initial sterilization is performed using a broad spectrum, highly-effective, low-toxicity bacteriacide, followed by trimming irregular portions.


2. Defatting: The fatty substances in the membrane are extracted with organic solvents using known tissue-treatment techniques.


3. Cross-linking and Fixation: The protein molecules in the membrane are crosslinked and fixed using a fixative, as described in greater detail hereinbelow.


4. Minimizing antigens: An active reagent is utilized to block the specific active groups such as —OH, —NH2, —SH, etc., in the proteins of the membrane, and a reagent with strong hydrogen bonding power is utilized to replace the specific hydrogen bonding in the spiral chains of the protein molecules in the membrane and alter its specific conformation.


5. Coupling of active layer: An active surface layer containing a specific polypeptide or glucosaminoglycan capable of adhering to growth factors is incorporated on the surface of the membrane through crosslinking and coupling using a coupling agent.


6. The two ends of the obtained biological membrane are fixed on the clip arms of the metal clip respectively using a medical adhesive.


Broad Spectrum Antibacterial Agents


The broad spectrum antibacterial agents in step 1 of the above method can be selected among benzalkonium bromide, sodium azide and chlorhexidine.


Organic Solvents


The organic solvents in step 2 of the above method can be selected among chloroform, ethyl acetate, anhydrous alcohol and mixtures thereof.


Fixative


The fixative applied in step 3 of the above method may be an epoxy compound that has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone. This fixative is described in U.S. Pat. No. 6,106,555, whose entire disclosure is incorporated by this reference as though set forth fully herein. Examples include an epoxide, a diamide, a diisocyanate, or a carbodiimide, in that the epoxide may be a monocyclic epoxide, or a bicyclic epoxide, or it may be a low poly(epoxide) (such as low poly(ethylene oxide), poly(propylene oxide) or a glycidyl ether).


Active Reagents


The active reagents in step 4 of the above method may be low molecular weight organic acid anhydrides, acyl chlorides, acylamides or monocyclic oxides, and the reagents having strong hydrogen bonding power are guanidine compounds.


Active Layer


The active layer in step 5 of the above method can contain a specific polypeptide capable of adhering to and accumulating growth factors, so that angiogenesis can be promoted. Examples of growth factors for blood vessels that can adhere to and accumulate include vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-bb) and vascular permeability factor (VPF). One example of the polypeptide is the polypeptide consisting of 16 lysines (K16), glycine (G), arginine (R), aspartic acid (D), serine (S), proline (P) and cysteine (C), and sequence of the composition is K16-G-R-G-D-S-P-C. The glucosaminoglycan can be hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetylated heparin sulfate or keratin sulfate


Coupling Agent for Active Layer


The coupling agent utilized for coupling the polypeptide or the glucosaminoglycan in step 5 of the above method may be a diamide, acid anhydride, epoxide, or other bifunctional reagent capable of undergoing a condensation reaction with —NH2, —OH, —COOH, etc.


The present invention provides the following advantages: The aneurysm clip carries a biological membrane having excellent biocompatibility for wrapping the circumference of the blood vessel at the clipped site, which prevents the aneurysm from worsening, and it can grow together with the outer wall of the blood vessel, and thickens and strengthens the biological tissues, and has a good treatment effect with reliable safety.


EXAMPLE 1

Referring to FIGS. 1 and 2, the biological membrane-carrying aneurysm clip comprises a metal clip and a biological membrane 3. The metal clip includes a first clip bar 5 and a second clip bar 6 that mutually overlap each other. Each clip bar 5 and 6 can have a shape that looks approximately like the letter “S”. One end of each clip bar 5, 6 is connected to each other through a spring device 7. A first clip arm 1 extends perpendicularly from a half slip ring 9 on the other end of the second clip bar 6, and a second clip arm 2 extends perpendicularly from another half slip ring 8 on the other end of the first clip bar 5. In other words, the plane defined by the clip arms 1 and 2 is perpendicular to the planes defined by the S-shaped clip bars 5 and 6. The two opposing ends of the biological membrane 3 are rolled up, with one end wrapped around the first clip arm 1 and another end wrapped around the second clip arm 2 to form a receiving portion 10 that is defined by a generally U-shaped membrane sheath that appears to be sagging as it is supported by the clip arms 1 and 2. The length of the biological membrane 3 is about the same as the length of the circumference of the receiving portion 10 formed by combining the half slip rings 8 and 9, while the width of the biological membrane 3 is about the same as the length of the clip arms 1 and 2 (or can be extended out from the ends of the clip arms 1 and 2 by 1-2 mm).


An active surface layer 4 comprising a specific polypeptide or glucosaminoglycan capable of adhering and accumulating growth factors is furnished on the inner surface of the biological membrane 3 through a coupling agent. The inner surface of the membrane 3 is the surface that faces and contacts the blood vessel when in use. The specific polypeptide is a condensation product of 16 lysines (K16), glycine (G), arginine (R), asparagic acid (D), serine (S), proline (P) and cysteine (C). The glucosaminoglycan is hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, acetyl heparin sulfate or keratan sulfate. The biological membrane 3 is prepared by crosslinking and fixing and eliminating antigens on porcine, bovine or sheep diaphragm, omental fat, pericardial membrane or enteric membrane. The metal clip is made of stainless steel or titanium alloy for medical applications.


This biological membrane 3 can be made from the following steps, utilizing natural durable soft tissues from animals:


1. Pretreatment: Initial sterilization is performed using broad spectrum, highly-effective and low-toxicity bacteriacides such as benzalkonium bromide, sodium azide and chlorhexidine, followed by eliminating impurities and trimming irregular portions.


2. Defatting: The fatty substances in the membrane 3 are extracted with organic solvents such as chloroform, acetone, ethyl acetate, diethyl ether, anhydrous alcohol or mixtures thereof.


3. Cross-linking and Fixation: The protein molecules in the membrane 3 are crosslinked and fixed using a fixative. The fixative is one or two reagents selected from among epoxides, diamides, diisocyanates and carbodiimides, which can easily undergo crosslinking with protein molecules. Epoxides are preferred, and the epoxide may be monocyclic epoxides




embedded image



or bycyclic epoxides




embedded image



where R=CnH2n+1−, n=0-10.


4. Minimizing antigens: The active groups (such as —OH or —NH2 or —SH, etc.) at specific locations in the proteins of biological membrane 3 are closed by using an active reagent, and the specific hydrogen bonding on the spiral chains of the protein molecules of biological membrane 3 is replaced using a strong hydrogen bonding reagent. The activating reagent may be low molecular weight organic acid anhydrides, acyl chloride, acylamides or monocyclic oxides, and the strong hydrogen bonding reagent is a guanidine compound. The coupling agent may be a diamide or diacid anhydride or bycyclic oxide or other bifunctional reagent capable of undergoing a condensation reaction with —NH2 or —OH or —COOH, etc.


5. Surface modification: An active ingredient such as a specific polypeptide is deposited on the surface of the membrane 3 through coupling using a diamide, acid anhydride, epoxide or other bifunctional reagent capable of undergoing condensation with —NH2, —OH, —COOH, etc., to form the active surface layer 4 on the surface of the membrane.


Finally, the two ends of the treated biological membrane 3 are fixed on the clip arms 1 and 2 of the metal clip, respectively, using a medical adhesive, thereby obtaining the aneurysm clip according to one embodiment of the present invention.


While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention.

Claims
  • 1. An aneurysm clip, comprising: a biological membrane that is a natural animal tissue isolated from its host and having a substrate that has: (i) been fixed with crosslinking reagents, (ii) residual specific active groups in protein molecules of the substrate that have been blocked by at least one active reagent after fixation by the crosslinking reagents, (iii) specific conformation of protein molecules of the substrate altered by a reagent with strong hydrogen bonding power, and (iv) an active layer coupled thereto, the active layer including either a polypeptide or a glucosaminoglycan that has the ability to adhere growth factors after implantation;a metal clip having: a first clip bar and a second clip bar that are attached to each other in a biased manner;a first clip arm that extends from the second clip bar, and a second clip arm that extends from the first clip bar;wherein the biological membrane is coupled to the first and second clip arms in a manner that defines a curved receiving portion.
  • 2. The clip of claim 1, wherein the membrane has opposing first and second ends, with each end defining a lumen, with the lumen of the first end of the biological membrane receiving the first clip arm, and the lumen of the second end of the biological membrane receiving the second clip arm.
  • 3. The clip of claim 1, wherein the first clip arm extends in a plane that is perpendicular to the plane of the second clip bar, and the second clip arm extends in a plane that is perpendicular to the plane of the first clip bar.
  • 4. The clip of claim 1, wherein the substrate is fixed by an epoxide, a diamide, a diisocyanate, or a carbodiimide.
  • 5. The clip of claim 1, wherein the at least one active reagent to block specific active groups in the protein molecules of the substrate can be acid anhydrides, acryl chlorides, or acylamides.
  • 6. The clip of claim 4, wherein the epoxide has a hydrocarbon backbone, that is water-soluble, and which does not contain an ether or ester linkage in its backbone.
  • 7. The clip of claim 1, wherein the natural animal tissue is pericardium or peritoneum.
  • 8. The clip of claim 1, wherein the reagent with strong hydrogen bonding power is a guanidine compound.
Priority Claims (1)
Number Date Country Kind
2005 1 0036315 Aug 2005 CN national
US Referenced Citations (57)
Number Name Date Kind
3802437 Kees, Jr. Apr 1974 A
3974526 Dardik et al. Aug 1976 A
4083066 Schmitz et al. Apr 1978 A
4319363 Ketharanathan Mar 1982 A
4481009 Nashef Nov 1984 A
4597766 Hilal et al. Jul 1986 A
4765335 Schmidt et al. Aug 1988 A
4793344 Cumming et al. Dec 1988 A
5067962 Campbell et al. Nov 1991 A
5078744 Chvapil Jan 1992 A
5080670 Imamura et al. Jan 1992 A
5217492 Guire et al. Jun 1993 A
5290217 Campos Mar 1994 A
5416074 Rabaud et al. May 1995 A
5447536 Girardot et al. Sep 1995 A
5549666 Hata et al. Aug 1996 A
5733339 Girardot et al. Mar 1998 A
5741283 Fahy Apr 1998 A
5758420 Schmidt et al. Jun 1998 A
5891196 Lee et al. Apr 1999 A
5902338 Stone May 1999 A
5955110 Patel et al. Sep 1999 A
5976192 McIntyre et al. Nov 1999 A
5984858 Stone Nov 1999 A
6008292 Lee et al. Dec 1999 A
6063120 Stone May 2000 A
6090995 Reich et al. Jul 2000 A
6106555 Yang Aug 2000 A
6117979 Hendriks et al. Sep 2000 A
6177514 Pathak et al. Jan 2001 B1
6241981 Cobb et al. Jun 2001 B1
6251117 Kringel et al. Jun 2001 B1
6458889 Trolisas et al. Oct 2002 B1
6482584 Mills et al. Nov 2002 B1
6572650 Abraham et al. Jun 2003 B1
7053051 Hendriks et al. May 2006 B2
7060103 Carr, Jr. et al. Jun 2006 B2
7077851 Lutze et al. Jul 2006 B2
7674289 Xu Mar 2010 B2
7820871 Xu Oct 2010 B2
20010031743 Peterson et al. Oct 2001 A1
20010044654 Chen et al. Nov 2001 A1
20020042473 Trolisas et al. Apr 2002 A1
20020081564 Levy et al. Jun 2002 A1
20020091445 Sung et al. Jul 2002 A1
20020095218 Carr Jul 2002 A1
20020099448 Hiles et al. Jul 2002 A1
20020103542 Bilbo Aug 2002 A1
20020138152 Francis et al. Sep 2002 A1
20030013989 Obermiller et al. Jan 2003 A1
20040038257 Ishii et al. Feb 2004 A1
20040202625 Daniloff et al. Oct 2004 A1
20050119736 Zilla et al. Jun 2005 A1
20050136543 Torres et al. Jun 2005 A1
20050187140 Hunter et al. Aug 2005 A1
20050229323 Mills et al. Oct 2005 A1
20080195229 Quijano et al. Aug 2008 A1
Foreign Referenced Citations (23)
Number Date Country
1093566 Oct 1994 CN
1445003 May 1999 CN
1237889 Dec 1999 CN
1267201 Sep 2000 CN
1313741 Sep 2001 CN
1330528 Jan 2002 CN
1456363 Nov 2003 CN
1473551 Feb 2004 CN
1556715 Dec 2004 CN
1579342 Feb 2005 CN
1903144 Jan 2007 CN
101172165 May 2008 CN
0965310 Dec 1999 EP
1112725 Jul 2001 EP
6-319744 Nov 1994 JP
2003-513682 Apr 2003 JP
2003-531685 Oct 2003 JP
WO9417851 Aug 1994 WO
WO 9822158 May 1998 WO
WO0013612 Mar 2000 WO
WO0035374 Jun 2000 WO
WO 0032250 Jun 2000 WO
WO0232327 Apr 2002 WO
Related Publications (1)
Number Date Country
20070032806 A1 Feb 2007 US